All In MedTech

FDA Clearance Tracker · P990023-S016

CELLUGEL(R) OPHTHALMIC VISCOSURGICAL DEVICE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 9, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 9, 2016

Approved

Time to decision

84 days

Received Jun 17, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990023-S016
Device name
CELLUGEL(R) OPHTHALMIC VISCOSURGICAL DEVICE
Applicant location
Fort Worth, TX
Received
Jun 17, 2016
Decided
Sep 9, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P990023

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

Approval to replace the current product release intravitreal test with the inflammatory release assay (IRA) product release test.

Source documents

Other decisions for Alcon Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.